In recent years, immunotherapy based on immune checkpoint inhibitors has been successful in treating NSCLC, especially in patients with a high tumour mutation burden (TMB), CD8+ tumour cell infiltration, and programmed death-ligand 1 (PD-L1) expression (14). This evidence concerns the gene CD274 and non-small cell lung carcinoma.